Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sesamin in preparation of product for treating and/or preventing lymphoma

A technology of sesamin and lymphoma, applied in the field of lymphoma treatment, can solve the problem of little research on lymphoma

Active Publication Date: 2021-07-30
隋雨桐 +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect of sesamin on lymphoma is currently poorly studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sesamin in preparation of product for treating and/or preventing lymphoma
  • Application of sesamin in preparation of product for treating and/or preventing lymphoma
  • Application of sesamin in preparation of product for treating and/or preventing lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] 5×10 5 EL4 cells were subcutaneously injected into the right axilla of 6-8 week-old BALB / c female mice to establish a mouse T-cell lymphoma model. When the average tumor volume is about 100mm 3 At that time, the tumor-bearing mice were randomly divided into two groups for follow-up treatment. The mice in the treatment group were intraperitoneally injected with 10 mg / kg sesamin every 2 days, diluted with sterile phosphate buffered saline (PBS). Control group (NC) mice were intraperitoneally injected with the same volume of PBS solution. All mice were housed under specific pathogen-free (SPF) conditions and had free access to water and food. Tumor volumes were measured every two days. After 21 days, the mice were sacrificed, and the tumor tissues were collected and weighed. The result is as figure 1 shown. The tumor volume of the mice in the sesamin treatment group was significantly smaller than the tumor volume of the mice in the control group from about 11 days a...

Embodiment 2

[0039] The cell viability was determined by the CCK-8 method, and the specific method was as follows: 100 μL of cell suspension was prepared in a 96-well plate, with 2000 EL4 cells per well. The culture plate was pre-incubated for 24 h in the incubator (37°C, 5% CO 2 ). After 24h, stimulate with 10 μ M, 20 μ M and 40 μ M sesamin (dissolve sesamin in dimethyl sulfoxide (DMSO), and dilute sesamin with RPMI-1640 medium according to the experimental requirements to a final concentration of 10 μ M, 20 μ M and 50 μ M) Mouse T-cell lymphoma cell line EL4 cells (purchased from American ATCC Company) 48, 72 and 96h, EL4 cells in RPMI- 1640 medium at 37°C, 5% CO 2 cultured in a humidified incubator. After the specified time, add 10 μL of CCK8 solution to each well. The culture plate was incubated in the incubator for 1-4h, the absorbance at 450nm was measured with a microplate reader, and the cell viability was calculated according to the absorbance. If the OD value is not measured...

Embodiment 3

[0045] First, EL4 cells were treated with 10 μM, 20 μM and 40 μM sesamin for 72 hours, and the total protein of each group was extracted, and the protein expression levels of apoptosis-related markers in each group were detected by western blot method, including Bax, Bcl-2 and Caspase-3, internal reference For β-Tubulin, the specific method is the same as in Example 2, the only difference is that the primary antibody is Caspase-3 (1:1000), Bax (1:1000), Bcl-2 (1:1000), β-Tubulin (1:3000 ), the secondary antibody is the corresponding secondary antibody.

[0046] The result is as image 3 A and image 3 As shown in B, compared with the control group, the protein expression levels of apoptosis markers (Bax / Bcl-2 and cleaved-Caspase3) in different doses of sesamin treatment groups were significantly increased.

[0047] Secondly, EL4 cells were treated with 10 μM, 20 μM and 40 μM sesamin for 72 hours, and the apoptotic ratio (Annexin V+PI- and AnnexinV+PI+) of the EL4 cells treat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of sesamin in preparation of a product for treating and / or preventing lymphoma, and belongs to the technical field of lymphoma treatment. In-vitro and in-vivo experiments find that sesamin has an anti-tumor effect on lymphoma, and the pharmacological action of sesamin comprises inhibition of lymphoma growth and inhibition of lymphoma cell proliferation. Furthermore, it is found that the sesamin inhibits proliferation of lymphoma cells by promoting the PCD process of apoptosis, pyroptosis and autophagy of the lymphoma cells, and the sesamin further promotes apoptosis and pyroptosis of the lymphoma cells by inducing autophagy of the lymphoma cells. The pharmacological action of the sesamin on the T cell lymphoma is expanded, and a theoretical basis is provided for application of the sesamin in treatment of the T cell lymphoma.

Description

technical field [0001] The invention belongs to the technical field of lymphoma treatment, and in particular relates to the application of sesamin in the preparation of products for treating and / or preventing lymphoma. Background technique [0002] Lymphoma is a heterogeneous group of malignant tumors of the lymphatic system that can be induced by environmental, infectious and genetic factors. Lymphoma can invade various organs in the human body, and the prognosis depends on histological type, clinical factors and molecular characteristics. Lymphoma can be divided into Hodgkin Lymphoma (Hodgkin Lymphoma, HL) and non-Hodgkin Lymphoma (non-Hodgkin Lymphoma, NHL), and NHL accounts for about 90% of lymphoma. NHL can be divided into B-cell lymphoma, T-cell lymphoma and NK-cell lymphoma. Approximately 10-15% of NHL cases are T-cell lymphomas and NK-cell lymphomas. Tumors of mature T cell origin are known as peripheral T cell lymphomas (PTCLs), and most subtypes of PTCLs have a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/36A61P35/00A23L33/00
CPCA61K31/36A61P35/00A23L33/00A23V2002/00A23V2200/308
Inventor 隋雨桐孟子愉
Owner 隋雨桐
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com